Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

21.28 -0.20 (-0.93%)
Streaming Delayed Price Updated: 9:51 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharm Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Why Catalyst Pharmaceuticals Shares Are Moving
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results. 
Via Benzinga
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates
The guidance includes Catalyst's newest, and second, product. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
7 Core Stocks to Build a Solid Portfolio Around
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation. 
Via InvestorPlace
Here's How Much $1000 Invested In Catalyst Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
Earnings Outlook For Catalyst Pharmaceuticals
Via Benzinga
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
2 Growth Stocks to Invest $1,000 in Right Now
Both of these biopharmas have major catalysts that are in play or drawing near. 
Via The Motley Fool
2 Breakout Growth Stocks to Buy for the Long Haul
These two stocks are entirely different, but they both make shareholders richer. 
Via The Motley Fool
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
7 Smart Stock Picks for Cautious Investors
As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors. 
Via InvestorPlace
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharma Reveals Interim Q4 Earnings, Says Well Positioned For 2023
Via Benzinga
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
The 7 Best Growth Stocks to Buy for February 2023
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. 
Via InvestorPlace
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review
Stocks reacted well to uneven earnings and economic reports. 
Via Investor's Business Daily
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
Things aren't as bad as they might seem. 
Via The Motley Fool
How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback
Catalyst is adding to its portfolio with a $160 million deal. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. The... 
Via Benzinga
Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its... 
Via Benzinga
Dow, Nasdaq Boasting Triple-Digit Midday Lead
Investors seem intent on leaving last week's losses behind, as earnings season heats up. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps Over 300 Points; Crude Oil Up 1%
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday. The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500... 
Via Benzinga
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.